Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

27. august 2009 oppdatert av: Neurogen Corporation

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)

This is a clinical trial to be conducted at multiple Parkinson Study Group (PSG) sites in the USA. Patients with early Parkinson disease will be randomly allocated to one of 4 arms in the study. The 4 arms include 3 arms with different doses of aplindore MR tablets and 1 placebo arm. The study drug will be taken twice a day (BID). The study is blinded and neither subjects, nor the investigators, will know what treatment the subject is receiving. Investigational study drug will be adjusted to the assigned dosage and then maintained at that dosage for the balance of the 12 week follow-up period. The entire study will take about 13 weeks. The study will assess the safety and tolerability of aplindore and measure how effective aplindore is in improving movement and other effects of Parkinson disease.

Studieoversikt

Status

Avsluttet

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

One hundred and sixty eight patients will be randomly assigned to one of four investigational treatment regimens in this outpatient study. For active treatment arms, study drug will be titrated to the assigned dosage and then maintained for up to a 12 week follow-up period before receiving tapered doses in advance of study completion. Dosing will take place over a total of about 13 weeks.

Studietype

Intervensjonell

Registrering (Faktiske)

9

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • Alabama
      • Birmingham, Alabama, Forente stater, 35294
        • University of Alabama At Birmingham (052)
    • Arizona
      • Scottsdale, Arizona, Forente stater, 85259
        • Mayo Clinic Arizona (060)
    • California
      • Sunnyvale, California, Forente stater, 94085
        • The Parkinson's Institute (012)
    • Colorado
      • Englewood, Colorado, Forente stater, 80113
        • Colorado Neurological Institute (052)
    • Connecticut
      • Danbury, Connecticut, Forente stater, 06810
        • Associated Neurologists, PC (190)
      • Manchester, Connecticut, Forente stater, 06040
        • Eastern Connecticut Neurology Specialists (215)
      • New Haven, Connecticut, Forente stater, 06510
        • Institute for Neurodegenerative Disorders (034)
    • Florida
      • Boca Raton, Florida, Forente stater, 33486
        • Parkinson's Disease & Movement Disorders Center of Boca Raton (196)
      • Miami, Florida, Forente stater, 33136
        • University of Miami (014)
      • Tampa, Florida, Forente stater, 33606
        • University of South Florida (019)
    • Illinois
      • Springfield, Illinois, Forente stater, 62794
        • Southern Illinois University (138)
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • University of Kentucky (172)
      • Louisville, Kentucky, Forente stater, 40205
        • University of Louisville (087)
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70121
        • Ochsner Clinic Foundation (207)
      • Shreveport, Louisiana, Forente stater, 71103
        • LSU Health Science Center Shreveport (132)
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02118
        • Boston University (040)
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Washington University (027)
    • New York
      • Albany, New York, Forente stater, 12208
        • Albany Medical College (037)
      • Rochester, New York, Forente stater, 14618
        • University of Rochester (001)
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Duke University Medical Center (119)
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • University of Cincinnati/Cincinnati Children's Hospital (089)
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • University of Pennsylvania (018)
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Baylor College of Medicine (007)
    • Washington
      • Kirkland, Washington, Forente stater, 98034
        • Booth Gardner Parkinson's Care Center (220)
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Medical College of Wisconsin (104)

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female at least 30 years old;
  • Initial diagnosis of idiopathic PD must be within 5 years;
  • At least two of the following cardinal signs must be present: bradykinesia, resting tremor, and rigidity;
  • PD progression must be Stage 1 to 2.5 (inclusive) according to the modified Hoehn and Yahr classification system;
  • Have a score on the MoCA of at least 26;
  • Have a score on the Beck Depression Inventory II (BDI II) of less than 15;
  • Have a screening UPDRS (Part III) motor score of at least 10;
  • In good general health as determined by a thorough medical history and physical examination (including vital signs), neurological examination, 12-lead ECG, and clinical chemistry laboratory tests;
  • Females of childbearing potential must be using an acceptable method of contraception and have a negative serum pregnancy test at the screening and baseline visits. Acceptable methods of contraception are oral, intrauterine, implantable, injectable contraceptives, double barrier methods or condoms impregnated with spermicide. After screening, subjects using oral contraceptive methods of contraception must agree to add an additional method until 30 days after the last dose of study medication. Women on oral contraceptives or using cervical rings must have been using them for at least 1 month before the screening visit;
  • Male subjects with partners of childbearing potential must use adequate contraception during the study and for 3 months after the study;
  • Females receiving hormone replacement therapy must be on a stable regimen for at least 3 months;
  • Able to read, understand, and provide written/dated informed consent before enrolling in the study, and must be willing to comply with all study procedures.

Exclusion Criteria:

  • History or clinical features consistent with an atypical parkinsonian syndrome;
  • History of surgical intervention for PD;
  • History of severe allergic or anaphylactic reaction to any drug;
  • History of allergies or known sensitivity, hypersensitivity, or severe adverse reaction (e.g., requiring abrupt discontinuation) to any drug similar to aplindore;
  • Taking prescription drug therapy or over the counter medication for chronic medical conditions who have not been on stable doses for at least 1 month before the screening visit;
  • Treated with L-dopa within 2 months before the baseline visit or who have had cumulative treatment exceeding 2 months;
  • Have taken dopamine agonist therapy within 1 month before the baseline visit or who have taken dopamine agonist therapy for a cumulative period exceeding 2 months;
  • Are receiving amantadine, anticholinergics, or monoamine oxidase B inhibitors who have not been taking stable doses for at least 2 months before the baseline visit;
  • A clinically significantly abnormal clinical laboratory value as judged by the investigator or a value that is disapproved by the study Clinical Monitor;
  • A decrease in either systolic blood pressure of at least 40 mmHg or a decrease in diastolic blood pressure of at least 20 mmHg following 5 minutes supine and 2 minutes standing, at or within 6 months before the baseline visit;
  • Clinically significant ECG findings, including prolonged QTcF intervals (>450 msec for men, >470 msec for women);
  • Evidence of clinically significant unstable allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease;
  • History of basal or squamous cell skin cancers or carcinoma in situ of the cervix within 2 years before the screening visit are excluded; for all other cancer diagnoses, subjects with a history within 5 years before the screening visit are excluded;
  • Any condition that may significantly affect drug absorption;
  • Pregnant or lactating females;
  • History or evidence of drug abuse or alcoholism as defined by DSM-IV TR within 12 months before the baseline visit or evidence of current withdrawal from drugs or alcohol before the baseline visit;
  • Prior exposure to aplindore;
  • Received any investigational drug within 60 days before the baseline visit.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: 4
Placebo
Legemiddel: aplindore MR tablets or Placebo
aplindore MR tablets administered BID for about 13 weeks
Eksperimentell: 1
aplindore 2 mg MR total daily dose
Legemiddel: aplindore MR tablets or Placebo
aplindore MR tablets administered BID for about 13 weeks
Eksperimentell: 2
aplindore 6 mg MR total daily dose
Legemiddel: aplindore MR tablets or Placebo
aplindore MR tablets administered BID for about 13 weeks
Eksperimentell: 3
aplindore 12 mg MR total daily dose
Legemiddel: aplindore MR tablets or Placebo
aplindore MR tablets administered BID for about 13 weeks

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Mean change from baseline to end of treatment in the combined scores of Parts II and III of the UPDRS
Tidsramme: 3 months
3 months

Sekundære resultatmål

Resultatmål
Tidsramme
The responder rate; Part II and Part III scores (separately) of the UPDRS; mean change from baseline in the modified Schwab and England Activities of Daily Living; time course in UPDRS and in modified S&E-ADL; safety and tolerability of aplindore MR
Tidsramme: 3 months
3 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Neurogen Corporation

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. desember 2008

Primær fullføring (Forventet)

1. august 2009

Studiet fullført (Forventet)

1. oktober 2009

Datoer for studieregistrering

Først innsendt

15. desember 2008

Først innsendt som oppfylte QC-kriteriene

15. desember 2008

Først lagt ut (Anslag)

17. desember 2008

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

28. august 2009

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. august 2009

Sist bekreftet

1. august 2009

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • Aplindore-211

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere